Skip to Content Skip to Search

Vaccines independent medical education

GSK Vaccines: Support for Independent Medical Education

Independent Medical Education (IME) projects eligible for GSK Vaccines’ support via this application process include educational activities in general vaccinology or specific disease areas in which GSK Vaccines has marketed products.

Should your organization wish to seek funding for an IME in any of the GSK areas of interest (see below), please submit your request online via the portal GSK Vaccines Grants & Donations Portal

For funding requests targeting a single country, local GSK offices should be contacted.

For US-based organizations requesting grant funding to support IME activities for US-based healthcare professionals, different guidelines apply, and this process is not applicable. Please visit for details.

The target recipients of the IME supported by this program should come from a broad international audience.

Recipient programs will develop the knowledge and practice of healthcare professionals in order that they can make the most appropriate curative or preventive treatment decisions for their patients.

IMEs must be free from GSK influence on content development and faculty, participant and logistic selection. IME programs developed in this independent way provide a balanced perspective on the subject matter, putting the patient first.  Organizations will be assessed according to defined criteria (see below).

GSK Vaccines Grants & Donations Portal

Areas of interest for Independent Medical Education

GSK Vaccines has identified areas of interest where we and others have seen gaps in medical education related to disease areas where GSK has marketed products, as well as in general areas of vaccinology.

These are shared to enable organizations that have the skills, capability and credentials to deliver high-quality medical education to submit requests for funding from GSK to support such programmes.

Criteria for Independent Medical Education

GSK Vaccines will evaluate requests for funding based on essential criteria which include:

  • Assessment of the type of organization requesting funding (Academic institution that trains healthcare professionals/ medical education charity that educates healthcare professionals/ patient group/ professional medical or scientific association or society/ healthcare service provider that employs healthcare professionals)
  • Evidence of complete independence from any promotional activities related to GSK
  • Absence of Conflicts of Interest in delivering medical education and in receiving funding from GSK
  • Agreement from the recipient programme to be subject to potential independent audit to review quality of education delivered and use of funds provided.

Other local requirements and legislation related to medical education will also be considered.

Contact for Independent Medical Education

Should your organization wish to seek funding in any of the areas of interest, please contact us using our dedicated Contact Form. Details of the process for submissions will be available via the Portal . 

Timelines for Independent Medical Education Grant Requests

Please note that Grants requests will be reviewed twice a year, in June and in December. Hence, IME proposals must be submitted by May 15th for the GSK June review and by November 15th for the GSK review of December each year.

Areas of Interest for Independent Medical Education

Herpes Zoster

  • Herpes Zoster disease awareness
  • The epidemiology, clinical burden and public health impact of Herpes Zoster (HZ) disease
  • Awareness of HZ complications and secondary health outcomes
  • Understanding the underlying risk drivers for HZ, including immunosuppression as a consequence of age, underlying disease or immunosuppressive therapies/treatment
  • Health care provider attitudes towards HZ, and the importance of prevention and vaccination as a key tool in preventing HZ
  • Understanding potential barriers to HZ vaccination in older adults and those at increased risk due to underlying disease or immunosuppressive therapies/treatment or co-morbid conditions
  • Effectiveness, impact and safety of HZ vaccination programs
  • Effective introduction, implementation, and maintenance of effective HZ vaccination programs within the COVID pandemic environment
  • Effective communication with regards to reactogenic vaccines from Health Care Professional (HCP) to patients
  • The ever-present risk of HZ and the importance of continued adult vaccination in the time of COVID pandemic

Meningococcal meningitis prevention

  • Addressing challenges on meningococcal vaccination during and post-COVID pandemic, and importance to completing vaccination course
  • Understanding MenB vaccination programs, implementation, learning and challenges
  • Duration of protection, timing and or need for booster vaccination
  •  Understanding/optimizing vaccination strategies with MenB and MenACWY


  • Disease, diagnosis, epidemiology and burden including long-term sequalae
  • Risk factors and their biological mechanisms to increased susceptibility and severity of RSV infection
  • Appropriate diagnosis and management of viral versus bacterial respiratory infections
  • Public health, patient & carer benefits to diagnosis
  • RSV testing and surveillance best practices and guidelines, inclusive of different healthcare systems
  • Clinical interaction of RSV and other respiratory pathogens 

Measles, mumps, rubella and varicella virus prevention

  • Burden of moderate to severe varicella disease – (hospitalisations, complications, Congenital Varicella Syndrome, sequelae)
  • Social impact of varicella disease for parents, workers, employers
  • The impact/benefit of vaccinating against varicella (both medical impact and direct/indirect cost effectiveness)
  • Education about benefits and convenience of concomitant varicella and zoster vaccination

Pediatric primary combination vaccination

  • Diphteria, Tetanus, Polio, Hib Control
  • Role of DTP combination vaccines in Hep B control
  • Role of IPV in polio end game strategy
  • Primary Vaccination in neonates including pre-terms


  • Pertussis Prevention strategies
  • Pertussis Maternal immunization
  • Pertussis burden in neonates, older adults and other risk groups
  • Vaccination impact on Pertussis carriage and transmission?

Pediatric pneumococcal diseases prevention

  • The burden of pediatric pneumococcal disease
  • Efficacy, impact and safety of pneumococcal conjugate vaccines (PCV)
  • Experience with implementation of pneumococcal conjugate vaccines
  • Cost effectiveness of pneumococcal vaccines

Rotavirus Prevention and Disease control

  • Rotavirus Gastroenteritis is more than just diarrhoea - Appreciating true burden of rotavirus disease and need for its prevention through vaccination in children under 5 years of age
  • HCPs play an important role as advocates in raising awareness and effectively counselling parents on the importance of Rotavirus vaccination for the prevention of RVGE: Sharing experience from Health Care Providers daily practices
  • Understanding the Full Public Health Value of Rotavirus vaccination – Moving towards UMV approach for higher coverage of RV vaccination and better disease control
  • Recognising the importance of Early vaccination against Rotavirus disease and valuing its significant impact

Influenza (Flu) virus prevention

  • Childhood seasonal influenza vaccination: awareness, coverage, vaccines effectiveness, burden of disease, in North America, Europe and International.
  • Burden of disease of seasonal influenza in pregnant woman, and infants (worldwide) and experience with seasonal influenza vaccination (TIV and QIV)
  • Childhood and school based influenza vaccination programs and strategies (Introduction of new programs, impact of vaccination, herd effect/indirect protection)
  • Influenza burden of disease and impact of vaccination against different flu strains in US, Europe and International
  • Pandemic preparedness

Human Papilloma Virus (HPV) prevention

  • Cervical Cancer Disease awareness in Asia and Latin America
  • Effectiveness and safety of Cervical Cancer Prevention through vaccination
  • Effective introduction and maintenance of vaccination programs
  • 1-dose schedule
  • Head and Neck Cancer

Combined Hepatitis A and Hepatitis B vaccine

  • Benefits of using a combined hepatitis A and B vaccine
  • Co-administration of hepatitis A and hepatitis B vaccines with COVID vaccines

Hepatitis B Virus (HBV) prevention

  • The public health impact of hepatitis B vaccines
  • Identification of gaps in implementation of hepatitis B recommendations
  • Use of monovalent hepatitis B vaccines vs combination vaccines

Hepatitis A Virus (HAV) prevention

  • Updated epidemiology: shifting endemicity and low endemic markets
  • Awareness of recommendations and target populations for vaccination
  • Impact of hepatitis A vaccination programmes

General vaccination topics

  • Societal and economic barriers for providers and population to vaccination for all ages (in particular for adults and older adults)
  • Health challenges in vaccination and impact of misinformation pandemic (“infodemic”) on vaccination
  • Behavioural science and behavioural economics applied to vaccination
  • Impact of communication interventions to HCPs or general public on vaccination using digital platforms and channels
  • Vaccination strategies including new technologies to support healthy ageing and for overcoming the age-related decline in immunity
  • Educational initiative using materials, innovative tools to help people of any age understand vaccination, including serious gaming
  • Innovative solutions for educational activities aiming to improve vaccine awareness
  • Vaccination as contribution to healthy lifestyle, multidisciplinary approach to prevention
  • Impact of infectious diseases (IDs) and vaccine preventable IDs in older adults’ morbidity and mortality, and in relation to the frailty index
  • The role and value of vaccine solutions beyond the simple cost/benefit assessment of vaccines to support life-course immunisation and healthy ageing
  • Capacity building and training of experts to improve education related to vaccination
  • Education related to vaccination for Medical and Health Science schools or post-graduate courses
  • Education related to vaccination for Pharmacists
  • Challenges and solutions to implement life course immunization (in particular the need for booster doses to keep protection)
  • Herd immunity: how to get it and how to maintain it - the importance of vaccination coverage across vaccines
  • Immunosenecensce and vaccine-preventable diseases
  • Impact of infectious diseases (IDs) and vaccine preventable IDs in older adults’ morbidity and mortality, and in relation to the frailty index and in older adults with comorbidities
  • The role and value of vaccine solutions beyond the simple cost/benefit assessment of vaccines to support adult vaccination and healthy ageing
  • Educational case studies of vaccine-preventable diseases in adults with patient testimonials
  • Education on how to sustain vaccination in post-pandemic setting including managing practice to keep up with immunizations in a virtual setting
  • Educational activities to address disparities and inequalities in society impacting coverage rates